Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares conducted on April 10, 2026. The filing was submitted on April 13, 2026. The transaction was executed through BNP Paribas SA as part of the Company's existing share buyback programme, pursuant to a non-discretionary agreement announced on February 17, 2026.
Key Financial Metrics and Transaction Details
The filing details a specific share repurchase event rather than providing comprehensive financial statements (revenue, profit, or cash flow are not included in this document).
- Shares Purchased: 325,000 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 2,157.00 GBp; highest price paid was 2,196.00 GBp.
- Average Price: Volume-weighted average price paid was 2,182.28 GBp.
- Treasury Holdings: Following this purchase, the Company holds 258,112,615 ordinary shares in treasury.
- Shares in Issue: 4,058,078,154 ordinary shares (excluding Treasury shares).
- Voting Rights: Treasury shares represent 6.36% of the total voting rights.
Material Changes and Programme Progress
Since the commencement of the current buyback agreement on February 17, 2026, the Company has purchased a total of 18,221,521 ordinary shares. The April 10 transaction represents a continuation of this programme. The filing confirms that the purchased shares are held as Treasury shares and do not carry voting rights.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement noting that forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from projections. Investors are referred to the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2025 for a detailed description of these risks.
Important Facts for Investor Verification
- Verify the total remaining capacity of the buyback programme announced on February 17, 2026, to assess future capital return potential.
- Confirm the impact of the 6.36% treasury share holding on earnings per share (EPS) calculations and voting thresholds.
- Review the Annual Report on Form 20-F for 2025 for the full list of risk factors referenced in the cautionary statement.
- Note that this filing reports a single day's activity (April 10, 2026) and does not reflect the Company's full quarterly or annual financial performance.